Article Text

Download PDFPDF
Resolution of warfarin-induced alopecia with conversion to apixaban
  1. Katherine Leigh Hull1,2,
  2. Richard Gooding3 and
  3. James O Burton1,2,4
  1. 1Cardiovascular Sciences, University of Leicester, Leicester, UK
  2. 2John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK
  3. 3Haematology, University Hospitals of Leicester NHS Trust, Leicester, UK
  4. 4School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK
  1. Correspondence to Dr Katherine Leigh Hull; katherine.hull{at}


Warfarin is frequently prescribed as a long-term anticoagulant in patients with end-stage kidney disease as direct oral anticoagulants undergo renal excretion. Anticoagulation is a rare cause of alopecia in adults and is thought to be due to the promotion of the ‘resting phase’ of hair follicles. In this case report, a prevalent haemodialysis female patient required long-term anticoagulation following a complex pulmonary embolus and dialysis access complications. After commencing warfarin therapy, the patient reported generalised loss and thinning of her hair. All other potential causes were excluded. Cessation of warfarin therapy and conversion to apixaban with close monitoring alleviated the hair loss. Warfarin therapy is a rare cause of alopecia but should be considered in patients on long-term anticoagulation when other diagnoses have been excluded. Hair loss has a profoundly negative impact on patient quality of life and should prompt investigation to determine the underlying cause.

  • haematology (drugs and medicines)
  • renal system
  • unwanted effects / adverse reactions
  • chronic renal failure
  • dialysis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @KatherineHulll, @@drjamesburton

  • Contributors KLH gained consent from the patient and prepared the manuscript. JB and RG maintained clinical oversight of the case and confirmed the accuracy of the report. All authors approved the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.